Crossfire Oncology Overview
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Crossfire Oncology General Information
Description
Developer of kinase inhibitors for precision medicine designed to treat cancer patients. The company engages in the research of molecular drugs through cell-based assays, protein crystallography, and medicinal chemistry, and develops therapeutic services for oncology, autoimmune diseases, and neurodegenerative diseases, enabling healthcare providers to treat acquired drug resistance observed in cancer patients treated with first-generation inhibitors.
Contact Information
Website
www.crossfire-oncology.comCorporate Office
- Pivot Park, RE1210
- Kloosterstraat 9
- 5349 AB Oss
- Netherlands
Corporate Office
- Pivot Park, RE1210
- Kloosterstraat 9
- 5349 AB Oss
- Netherlands
Crossfire Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 10-Sep-2024 | Completed | Clinical Trials - Phase 2 | |||
| 3. Grant | 12-May-2014 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 06-Jun-2012 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Jan-2010 | Completed | Startup |
Crossfire Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Crossfire Oncology Patents
Crossfire Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025266872-A1 | Bifunctional compounds capable of inducing degradation of polo-like kinase1 | Pending | 30-Apr-2024 | ||
| WO-2025228947-A1 | Bifunctional compounds capable of inducing degradation of polo-like kinase1 | Pending | 30-Apr-2024 | ||
| WO-2024245578-A1 | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor | Inactive | 02-Jun-2023 | ||
| WO-2024245577-A1 | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor | Inactive | 02-Jun-2023 | ||
| EP-4293019-A1 | 4-substituted (1h-benzo[d]imidazol-2-yl)-1h-pyrazoles as bub1 inhibitors useful for treating cancers | Inactive | 13-Jun-2022 | C07D403/14 |
Crossfire Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Crossfire Oncology Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brabantse Ontwikkelings Maatschappij | Venture Capital | Minority |
Crossfire Oncology FAQs
-
Where is Crossfire Oncology headquartered?
Crossfire Oncology is headquartered in Oss, Netherlands.
-
What is the size of Crossfire Oncology?
Crossfire Oncology has 15 total employees.
-
What industry is Crossfire Oncology in?
Crossfire Oncology’s primary industry is Drug Discovery.
-
Is Crossfire Oncology a private or public company?
Crossfire Oncology is a Private company.
-
What is Crossfire Oncology’s current revenue?
The current revenue for Crossfire Oncology is .
-
Who are Crossfire Oncology’s investors?
Brabantse Ontwikkelings Maatschappij has invested in Crossfire Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
